Joseph Wallins, Sara Saravia, Olayiwola Bolaji, Zohaib Shaikh, Anthony Yu
{"title":"乳腺癌的心脏肿瘤学考虑：风险分层、监测和治疗。","authors":"Joseph Wallins, Sara Saravia, Olayiwola Bolaji, Zohaib Shaikh, Anthony Yu","doi":"10.46883/2025.25921044","DOIUrl":null,"url":null,"abstract":"<p><p>Long-term outcomes of patients with breast cancer have steadily improved due to advances in early detection and cancer therapeutics. Cardiovascular disease (CVD) is a leading cause of non-cancer-related mortality in this population, and this has been attributed to the cardiovascular toxicity of common breast cancer treatments including chemotherapy and radiation as well as shared risk factors between cancer and CVD. Identifying patients at risk of developing treatment-related cardiotoxicities is crucial to inform clinical decisions regarding surveillance, prevention, and management. In this review, we provide a broad overview of the treatment-related cardiotoxicities associated with common breast cancer treatment. We present data on risk-stratification tools for oncologists, including when to refer to a cardiologist, as well as recommendations for cardiovascular testing tailored to individual treatment regimens. Lastly, we review recent trial data on preventive and therapeutic approaches to treatment-related cardiotoxicities, and future directions that may lead to improved cardiovascular outcomes in this population.</p>","PeriodicalId":51147,"journal":{"name":"Oncology-New York","volume":"null 5","pages":"188-197"},"PeriodicalIF":1.8000,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Cardio-Oncology Considerations for Breast Cancer: Risk Stratification, Monitoring, and Treatment.\",\"authors\":\"Joseph Wallins, Sara Saravia, Olayiwola Bolaji, Zohaib Shaikh, Anthony Yu\",\"doi\":\"10.46883/2025.25921044\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Long-term outcomes of patients with breast cancer have steadily improved due to advances in early detection and cancer therapeutics. Cardiovascular disease (CVD) is a leading cause of non-cancer-related mortality in this population, and this has been attributed to the cardiovascular toxicity of common breast cancer treatments including chemotherapy and radiation as well as shared risk factors between cancer and CVD. Identifying patients at risk of developing treatment-related cardiotoxicities is crucial to inform clinical decisions regarding surveillance, prevention, and management. In this review, we provide a broad overview of the treatment-related cardiotoxicities associated with common breast cancer treatment. We present data on risk-stratification tools for oncologists, including when to refer to a cardiologist, as well as recommendations for cardiovascular testing tailored to individual treatment regimens. Lastly, we review recent trial data on preventive and therapeutic approaches to treatment-related cardiotoxicities, and future directions that may lead to improved cardiovascular outcomes in this population.</p>\",\"PeriodicalId\":51147,\"journal\":{\"name\":\"Oncology-New York\",\"volume\":\"null 5\",\"pages\":\"188-197\"},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2025-06-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oncology-New York\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.46883/2025.25921044\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology-New York","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.46883/2025.25921044","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
Cardio-Oncology Considerations for Breast Cancer: Risk Stratification, Monitoring, and Treatment.
Long-term outcomes of patients with breast cancer have steadily improved due to advances in early detection and cancer therapeutics. Cardiovascular disease (CVD) is a leading cause of non-cancer-related mortality in this population, and this has been attributed to the cardiovascular toxicity of common breast cancer treatments including chemotherapy and radiation as well as shared risk factors between cancer and CVD. Identifying patients at risk of developing treatment-related cardiotoxicities is crucial to inform clinical decisions regarding surveillance, prevention, and management. In this review, we provide a broad overview of the treatment-related cardiotoxicities associated with common breast cancer treatment. We present data on risk-stratification tools for oncologists, including when to refer to a cardiologist, as well as recommendations for cardiovascular testing tailored to individual treatment regimens. Lastly, we review recent trial data on preventive and therapeutic approaches to treatment-related cardiotoxicities, and future directions that may lead to improved cardiovascular outcomes in this population.
期刊介绍：
Although laboratory and clinical cancer research need to be closely linked, observations at the basic level often remain removed from medical applications. This journal works to accelerate the translation of experimental results into the clinic, and back again into the laboratory for further investigation. The fundamental purpose of this effort is to advance clinically-relevant knowledge of cancer, and improve the outcome of prevention, diagnosis and treatment of malignant disease. The journal publishes significant clinical studies from cancer programs around the world, along with important translational laboratory findings, mini-reviews (invited and submitted) and in-depth discussions of evolving and controversial topics in the oncology arena. A unique feature of the journal is a new section which focuses on rapid peer-review and subsequent publication of short reports of phase 1 and phase 2 clinical cancer trials, with a goal of insuring that high-quality clinical cancer research quickly enters the public domain, regardless of the trial’s ultimate conclusions regarding efficacy or toxicity.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
